Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Novo Nordisk

Insulet

Tandem Diabetes Care

Diabetes-device makers' stocks are breaking out of ‘GLP-1 jail' ahead of schedule, analysts say, after months of stock-market punishment based on fears that the popular obesity drugs would clobber the market for their products.

Diabetes stocks jump as obesity-drug recovery comes ahead of schedule, analysts say

Dexcom, Inc. (NASDAQ:DXCM ) Q3 2023 Earnings Conference Call October 26, 2023 4:30 PM ET Company Participants Sean Christensen - Director, Corporate Affairs & Head of IR Kevin Sayer - Executive Chairman, CEO & President Jereme Sylvain - EVP, CFO & CAO Jake Leach - EVP, Chief Operating Officer Terry Lauver - Chief Commercial Officer Conference Call Participants Robert Marcus - JPMorgan Chase & Co. Margaret Kaczor - William Blair & Company Larry Biegelsen - Wells Fargo Securities Danielle Antalffy - UBS Matt Taylor - Jefferies Matthew O'Brien - Piper Sandler & Co. Mathew Blackman - Stifel, Nicolaus & Company Joanne Wuensch - Citigroup Jeff Johnson - Robert W. Baird & Co. Travis Steed - Bank of America Merrill Lynch Marie Thibault - BTIG Caitlin Cronin - Cannacord Genuity Jayson Bedford - Raymond James & Associates Michael Polark - Wolfe research Steve Lichtman - Oppenheimer Josh Jennings - TD Cowen Matt Miksic - Barclays Bank Mike Kratky - Leerink Partners Operator Welcome to the Dexcom Third Quarter 2023 Earnings Release Conference Call.

Dexcom, Inc. (DXCM) Q3 2023 Earnings Call Transcript

DexCom (DXCM) came out with quarterly earnings of $0.50 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.28 per share a year ago.

DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates

Dexcom topped third-quarter expectations Thursday, shrugging off concerns new weight-loss drugs would undercut its sales. DXCM stock popped.

Dexcom Shrugs Off Pressure From Weight-Loss Drugs, Boosts 2023 Outlook. Stock Pops 14%.

Shares of DexCom Inc. DXCM, -3.86% shot up 15.3% to pace the S&P 500's SPX, -1.18% after-hours gainers on Thursday, after of maker of glucose monitoring systems reported third-quarter profit that beat expectations by a wide margin, and boosted its revenue outlook. Net income rose to $120.7 million, or 29 cents a share, from $101.2 million, or 24 cents a share, in the year-ago period.

Glucose monitor maker DexCom's stock soars after big earnings beat, raised revenue outlook as real-time monitoring awareness grows

Medical device maker Dexcom on Thursday raised its annual revenue forecast and beat quarterly estimates on strong demand for its continuous glucose monitoring (CGM) devices, sending its shares more than 11% higher in extended trading.

Dexcom lifts 2023 revenue view on strong demand for diabetes devices

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #Dexcom--Dexcom Reports Third Quarter 2023 Financial Results, Raises 2023 Revenue and Margin Guidance, and Announces $500 Million Share Repurchase Program.

Dexcom Reports Third Quarter 2023 Financial Results, Raises 2023 Revenue and Margin Guidance, and Announces $500 Million Share Repurchase Program

Vertex Pharmaceuticals

The stock market may be volatile, but investors don't have to wait on the sidelines. Vertex Pharmaceuticals is forging its own path in the rare disease drug market.

2 Best Healthcare Stocks to Buy Right Now

DexCom's (DXCM) third-quarter 2023 results are likely to reflect rising volumes across all channels.

DexCom (DXCM) to Report Q3 Earnings: Is a Beat in Store?

Avantor Inc.

Catalent

Danaher

Inspire Medical Systems Inc

Coca-Cola

Eli Lilly

PepsiCo

Repligen

Thermo Fisher Scientific

Walmart

Citing Vanda Research, the Wall Street Journal reports that the average individual-investor stock portfolio is up 150% since the start of 2014, versus around 140% for the S&P 500's SPX during the same period.

The weight-loss drugs are coming for these companies — but here's why Coke, others, may be spared, says JPMorgan

DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DexCom (DXCM) Earnings Expected to Grow: Should You Buy?

Applied Materials

ASML Hld

Broadcom

Cisco Systems

Diamondback Energy

Fastenal

Nasdaq stocks generally equate to higher-growth, technology-dominated firms in the eyes of most investors. The index is generally more rate-sensitive than leading indexes like the Dow and the S&P 500.

The 7 Best Nasdaq Stocks To Buy Now: October 2023

Edwards Lifesciences

IQVIA Hlds

Medical Product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EW, PODD, DXCM and IQV are poised ahead of their earnings release.

4 Medical Product Stocks Set to Outpace Q3 Earnings Estimates

DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can DexCom (DXCM) Keep the Earnings Surprise Streak Alive?

Inmode Ltd

DexCom is a big name in diabetes care, and investors may be overly bearish on the stock. InMode recently downgraded its guidance as rising interest rates impact its sales activity.

2 Healthcare Stocks Near Their 52-Week Lows That Could Double in Value

Plenty of businesses, such as PepsiCo Inc. NYSE: PEP and Walmart Inc. NYSE: WMT, have been under the microscope on fears of potential earnings decreases due to growing use of products like Novo Nordisk A/S' NYSE: NVO Ozempic, and similar drugs made by Eli Lilly & Co. NYSE: LLY.

Is the Ozempic-Driven DexCom Selloff Overdone?

NVIDIA

Tesla

When stock-market volatility picks up, investors tend to gravitate to outperforming companies that have enacted stock splits. Nine high-profile companies have conducted forward-stock splits since the start of July 2021.

3 Stock-Split Stocks With 110% to 696% Upside, According to Select Wall Street Analysts and Pundits

Baxter

Penumbra

ResMed

Zimmer Biomet Hlds

Some investors have worried that new weight-loss drugs could undermine demand for some medical devices.

6 Medical Device Stocks Primed to Bounce Back

iShares U.S. Medical Devices ETF

Intuitive Surgical

September-quarter earnings among medical-device makers may prove better than expected in the age of weight-loss drugs.

MedTech Earnings in the Age of Ozempic May Not Be That Bad

The dramatic weight loss resulting from a new breed of diabetes medication has weighed on DexCom stock. As with all things, however, the devil is in the details.

Why DexCom Stock Rallied on Monday

DexCom's (DXCM) G7 CGM System (launched in Canada) is expected to combine simplicity and power, thereby providing a better way to manage diabetes.

DexCom (DXCM) to Launch Latest CGM System G7 in Canada

While stocks are taking a breather from their recent run, a bull market is on the horizon. Investor interest in stock-split stocks continues, as these stocks have historically generated strong gains over extended periods.

A Bull Market Is Coming: 2 Magnificent Stock-Split Growth Stocks That Could Soar 40% and 51%, According to Wall Street

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that its next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System will be available on October 10, 2023, for Canadians living with all types of diabetes ages two and older, including those who are pregnant. Its introduction brings the most accurate CGM on the market*,1 to Canadians, offering users a new.

Next-Generation Dexcom G7 Continuous Glucose Monitoring System Now Available in Canada

In recent months, diabetes stocks have retreated sharply, partly due to the increased popularity of the weight-loss drug Semaglutide. Some have contended that Semaglutide will greatly reduce the number of people suffering from diabetes in America.

Glucose Game-Changers: 3 Diabetes Stocks to Grab on the Downturn

Wall Street says insulin pump maker Insulet and Tandem Diabetes, as well as glucose-monitor maker DexCom, look ready to rise after pressure from Novo Nordisk's Wegovy and Eli Lilly.

News for DexCom Stock (DXCM)